Q4 EPS Estimate for Hims & Hers Health Raised by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at Leerink Partnrs upped their Q4 2024 earnings per share estimates for Hims & Hers Health in a report released on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.07 per share for the quarter, up from their previous forecast of $0.06. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.39 EPS.

A number of other analysts have also weighed in on the stock. Truist Financial upped their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Piper Sandler reiterated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Finally, Needham & Company LLC initiated coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $22.22 on Wednesday. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $25.74. The business has a 50 day simple moving average of $17.84 and a 200 day simple moving average of $17.99. The firm has a market capitalization of $4.77 billion, a price-to-earnings ratio of 277.78 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same period in the prior year, the firm earned ($0.03) EPS. The business’s quarterly revenue was up 51.8% on a year-over-year basis.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now owns 145,763 shares in the company, valued at $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now directly owns 145,763 shares of the company’s stock, valued at $2,960,446.53. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,334 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total value of $40,378.20. Following the sale, the insider now owns 164,475 shares in the company, valued at $2,845,417.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 860,719 shares of company stock worth $15,194,078. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC raised its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC grew its position in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. CWM LLC grew its position in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Amalgamated Bank grew its position in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.